Placenta growth factor induces 5-lipoxygenase-activating protein to increase leukotriene formation in sickle cell disease

Blood

Volumn 113, Issue 5, 2009, Pages 1129-1138

  Patel, Nitin ^a   Gonsalves, Caryn S ^a   Yang, Minyang ^b   Malik, Punam ^b   Kalra, Vijay K ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; HYDROXYUREA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOTRIENE; LUCIFERASE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PLACENTAL GROWTH FACTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMALL INTERFERING RNA; 5-LIPOXYGENASE-ACTIVATING PROTEIN; ARACHIDONATE 5 LIPOXYGENASE; CARRIER PROTEIN; HIF1A PROTEIN, HUMAN; MEMBRANE PROTEIN; PLACENTA PROTEIN; PRODUCT PLACENTA GROWTH FACTOR;

ARTICLE; CATALYSIS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; ENZYME INDUCTION; ERYTHROID CELL; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; SICKLE CELL ANEMIA; BIOSYNTHESIS; CELL LINE; CHILD; FEMALE; GENE EXPRESSION REGULATION; MALE; METABOLISM; PRESCHOOL CHILD; RESPIRATORY TRACT ALLERGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANEMIA, SICKLE CELL; ARACHIDONATE 5-LIPOXYGENASE; CARRIER PROTEINS; CELL LINE; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LEUKOTRIENES; MALE; MEMBRANE PROTEINS; NADPH OXIDASE; NF-KAPPA B; PREGNANCY PROTEINS; RESPIRATORY HYPERSENSITIVITY; RESPONSE ELEMENTS;

EID: 60849115556     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-169821     Document Type: Article

References (67)

1. Solovey A, Gui L, Ramakrishnan S, Steinberg MH, Hebbel RP. Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells. Blood. 1999;93:3824-3830.
2. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood. 2000; 96:2451-2459.
3. Kaul DK, Liu XD, Choong S, et al. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am J Physiol Heart Circ Physiol. 2004;287:H293-H301.
4. Croizat H, Nagel RL. Circulating cytokines response and the level of erythropoiesis in sickle cell anemia. Am J Hematol. 1999;60:105-115.
5. Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000;342:83-89.
6. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death [see comments]. N Engl J Med. 1994;330:1639-1644.
7. Hofstra TC, Kalra VK, Meiselman HJ, Coates TD. Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst. Blood. 1996;87:4440-4447.
8. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A. 2002;99:3047-3051.
9. Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with acute chest syndrome and pain in children with sickle cell anemia. Blood. 2006;108:2923-2927.
10. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350:886-895.
11. Koumbourlis AC, Zar HJ, Hurlet-Jensen A, Goldberg MR. Prevalence and reversibility of lower airway obstruction in children with sickle cell disease. J Pediatr. 2001;138:188-192.
12. Leong MA, Dampier C, Verlotta L, Allen JL. Airway hyperreactivity in children with sickle cell disease. J Pediatr. 1997;131:278-283.
13. Sylvester KP, Patey RA, Milligan P, et al. Impact of acute chest syndrome on lung function of children with sickle cell disease. J Pediatr. 2006;149: 17-22.
14. Wall MA, Platt OS, Strieder DJ. Lung function in children with sickle cell anemia. Am Rev Respir Dis. 1979;120:210-214.
15. Miller GJ, Serjeant GR, Saunders MJ, Richardson C, Gilson RJ. Interpretation of lung function tests in the sickle-cell haemoglobinopathies. Thorax. 1978;33:85-88.
16. Castro O, Gladwin MT. Pulmonary hypertension in sickle cell disease: mechanisms, diagnosis, and management. Hematol Oncol Clin North Am. 2005;19:881-896.
17. Minter KR, Gladwin MT. Pulmonary complications of sickle cell anemia. A need for increased recognition, treatment, and research. Am J Respir Crit Care Med. 2001;164:2016-2019.
18. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350:886-895.
19. Soberman RJ, Christmas P. The organization and consequences of eicosanoid signaling. J Clin Invest. 2003;111:1107-1113.
20. Samuelsson B, Dahle'n SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 1987;237:1171-1176.
21. Chu SJ, Tang LO, Watney E, Chi EY, Henderson Jr, WR. In situ amplification of 5-lipoxygenase and 5-lipoxygenase-activating protein in allergic airway inflammation and inhibition by leukotriene blockade. J Immunol. 2000;165:4640-464
22. Petasis NA, Akritopoulou-Zanze I, Fokin VV, et al. Design, synthesis and bioactions of novel stable mimetics of lipoxins and aspirin-triggered lipoxins. Prostaglandins Leukot Essent Fatty Acids. 2005; 73:301-321.
23. Werz O, Burkert E, Samuelsson B, Radmark O, Steinhilber D. Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. Blood. 2002;99:1044-1052.
24. -KB and C/EBP-mediated mechanism. Am J Physiol Cell Physiol. 2005;288:C1125-C1133.
25. Reddy KV, Serio KJ, Hodulik CR, Bigby TD. 5-Lipoxygenase-activating protein gene expression. Key role of CCAAT/enhancer-binding proteins (C/EBP) in constitutive and tumor necrosis factor (TNF)αinduced expression in THP-1 cells. J Biol Chem. 2003;278:13810-13818.
26. Setty BN, Stuart MJ. Eicosanoids in sickle cell disease: potential relevance of neutrophil leukotriene B4 to disease pathophysiology. J Lab Clin Med. 2002;139:80-89.
27. Jennings JE, Ramkumar T, Mao J, et al. Elevated urinary leukotriene E4 levels are associated with hospitalization for pain in children with sickle cell disease. Am J Hematol. 2008;83:640-643.
28. Persico MG, Vincenti V, DiPalma T. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). Curr Top Microbiol Immunol. 1999;237:31-40.
29. Hauser S, Weich HA. A heparin-binding form of placenta growth factor (PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors. 1993;9:259-268.
30. Desai J, Holt-Shore V, Torry RJ, Caudle MR, Torry DS. Signal transduction and biological function of placenta growth factor in primary human trophoblast. Biol Reprod. 1999;60:887-892.
31. Perelman N, Selvaraj SK, Batra S, et al. Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood. 2003;102: 1506-1514.
32. Tordjman R, Delaire S, Plouet J, et al. Erythroblasts are a source of angiogenic factors. Blood. 2001;97:1968-1974.
33. Selvaraj SK, Giri RK, Perelman N, et al. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood. 2003;102:1515-1524.
34. + stem cells from bone-marrow microenvironment. Nat Med. 2002;8:841-849.
35. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000;106:337-338.
36. Kim KS, Rajagopal V, Gonsalves C, Johnson C, Kalra VK. A novel role of hypoxia-inducible factor in cobalt chloride-and hypoxia-mediated expression of IL-8 chemokine in human endothelial cells. J Immunol. 2006;177:7211-7224.
37. Giri RK, Selvaraj SK, Kalra VK. Amyloid peptideinduced cytokine and chemokine expression in THP-1 monocytes is blocked by small inhibitory RNA duplexes for early growth response-1 messenger RNA. J Immunol. 2003;170:5281-5294.
38. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.
39. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T. Requirement for generation of H(2)O(2) for platelet-derived growth factor signal transduction. Science. 1995;270:296-299.
40. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983;11:1475-1489.
41. Hanze J, Eul BG, Savai R, et al. RNA interference for HIF-1α inhibits its downstream signalling and affects cellular proliferation. Biochem Biophys Res Commun. 2003;312:571-577.
42. Patel N, Gonsalves CS, Malik P, Kalra VK. Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxiainducible factor-1α. Blood. 2008;112:856-865.
43. Cianfarani F, Zambruno G, Brogelli L, et al. Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential. Am J Pathol. 2006;169:1167-1182.
44. Tchaikovski V, Fellbrich G, Waltenberger J. The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes. Arterioscler Thromb Vasc Biol. 2008;28:322-328.
45. Nolfo R, Rankin JA. U937 and THP-1 cells do not release LTB4, LTC4, or LTD4 in response to A23187. Prostaglandins. 1990;39:157-165.
46. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A. 1998;95:7987-7992.
47. McMahon S, Charbonneau M, Grandmont S, Richard DE, Dubois CM. Transforming growth factor β1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. J Biol Chem. 2006;281:24171-24181.
48. Quinn CT, Lee NJ, Shull EP, et al. Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn Cohort. Blood. 2008;111:544-548.
49. Bryant R. Asthma in the pediatric sickle cell patient with acute chest syndrome. J Pediatr Health Care. 2005;19:157-162.
50. Koumbourlis AC, Hurlet-Jensen A, Bye MR. Lung function in infants with sickle cell disease. Pediatric Pulmonol. 1997;24:277-281.
51. Ibe BO, Kuranstin-Mills J, Usharaj J, Lessin LS. Plasma and urinary leukotrienes in sickle cell disease: possible role in the inflammatory process. Eur J Clin Invest. 1994;24:57-64.
52. Styles LA, Schalkwijk CG, Aarsman AJ, et al. Phospholipase A2 levels in acute chest syndrome of sickle cell disease. Blood. 1996;87:2573-2578.
53. Ballas SK, Files B, Luchtman-Jones L, et al. Secretory phospholipase A2 levels in patients with sickle cell disease and acute chest syndrome. Hemoglobin. 2006;30:165-170.
54. Feisst C, Albert D, Steinhilber D, Werz O. The aminosteroid phospholipase C antagonist U-73122 (1-[6-[[17-β-3-methoxyestra-1,3,5(10)-trien-17-yl] amino]hexyl]-1H-pyrrole-2,5-dione) potently inhibits human 5-lipoxygenase in vivo and in vitro. Mol Pharmacol. 2005;67:1751-1757.
55. Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1α in vascular smooth muscle cells. J Biol Chem. 2000;275:26765-26771.
56. Szeto SSW, Reinke SN, Sykes BD, Lemire BD. Ubiquinone-binding site mutations in the Saccharomyces cerevisiae succinate dehydrogenase generate superoxide and lead to the accumulation of succinate. J Biol Chem. 2007;282:27518-27526.
57. Berchner-Pfannschmidt U, Yamac H, Trinidad B, Fandrey J. Nitric oxide modulates oxygen sensing by hypoxia-inducible factor 1-dependent induction of prolyl hydroxylase 2. J Biol Chem. 2007;282:1788-1796.
58. Gao P, Zhang H, Dinavahi R, et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell. 2007;12:230-238.
59. Kaelin J. ROS: really involved in oxygen sensing. Cell Metab. 2005;1:357-358.
60. Kennedy BP, Diehl RE, Boie Y, Adam M, Dixon RA. Gene characterization and promoter analysis of the human 5-lipoxygenase activating protein (FLAP). J Biol Chem. 1991;266:8511-8516.
61. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002;8:831-840.
62. Oura H, Bertoncini J, Velasco P, et al. A critical role of placental growth factor in the induction of inflammation and edema formation. Blood. 2003; 101:560-567.
63. Datta YH, Romano M, Jacobson BC, et al. Peptido-leukotrienes are potent agonists of von Willebrand factor secretion and P-selectin surface expression in human umbilical vein endothelial cells. Circulation. 1995;92:3304-3311.
64. Brady HR, Serhan CN. Adhesion promotes transcellular leukotriene biosynthesis during neutrophil-glomerular endothelial cell interactions: inhibition by antibodies against CD18 and L-selectin. Biochem Biophys Res Commun. 1992;186:1307-1314.
65. Nandedkar SD, Feroah TR, Hutchins W, et al. Histopathology of experimentally-induced asthma in a murine model of sickle cell disease. Blood. 2008;112:2529-2538.
66. Dube LM, Swanson L, Awni W. Zileuton, a leukotriene synthesis inhibitor in the management of chronic asthma. Clin Rev Allergy Immunol. 1999; 17:213-221.
67. Haynes Jr., J, Baliga BS, Obiako B, Ofori-Acquah S, Pace B. Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway. Blood. 2004; 103:3945-3950.